Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022Business Wire • 04/04/22
West Virginia Says J&J, Teva, AbbVie Caused 'Tsunami' Of Opioid Addiction: ReutersBenzinga • 04/04/22
Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual MeetingBusiness Wire • 04/01/22
Teva Reaches Agreement With Florida to Settle the State's Opioid-Related ClaimsBusiness Wire • 03/30/22
Teva stock jumps toward longest win streak in 2 years, after Bernstein analyst turns bullishMarket Watch • 03/25/22
Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.Business Wire • 03/07/22
Teva Canada Welcomes Public Drug Plan Reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the Non-Insured Health Benefits Program for Patients prescribed AJOVY® (fremanezumab) for the Preventive Treatment of Migraine in AdultsBusiness Wire • 03/02/22
Bleichmar Fonti & Auld LLP Announce a Proposed Class Action Settlement Involving Purchasers of Teva Pharmaceutical SecuritiesPRNewsWire • 02/21/22